What are the 2025 American Heart Association (AHA) recommendations for electrical and pharmacologic cardioversion, including anticoagulation requirements, drug dosing, and post‑cardioversion management?

2025 AHA Update on Cardioversion

The 2025 AHA guidelines recommend immediate defibrillation at 200 J for all patients with sustained polymorphic ventricular tachycardia and urgent electrical cardioversion for hemodynamically unstable atrial fibrillation/flutter, while maintaining the established anticoagulation protocols of at least 3 weeks before and 4 weeks after elective cardioversion for AF/flutter ≥48 hours duration. 1, 2

Key Updates from 2025 AHA Guidelines

Electrical Cardioversion Energy Settings

The 2025 guidelines represent a significant departure from previous incremental approaches:

• Start at 200 J for initial cardioversion rather than escalating from lower energies 2
• This approach demonstrates:
  • Greater initial shock success rates
  • Reduced likelihood of inducing ventricular fibrillation
  • Shorter anesthesia duration
  • Lower cumulative electrical burden

Polymorphic Ventricular Tachycardia

All adult patients with sustained polymorphic VT should receive immediate defibrillation (Class I, Level of Evidence B-NR), regardless of clinical stability 2. Previous editions suggested multiple treatment modalities based on stability, but this has been simplified to immediate electrical therapy.

Anticoagulation Requirements (Unchanged Core Principles)

While the 2025 update focuses on electrical aspects, the anticoagulation framework remains consistent with established protocols:

For AF/Flutter ≥48 Hours or Unknown Duration

Elective cardioversion requires:

• 3 weeks of therapeutic anticoagulation before cardioversion (warfarin INR 2.0-3.0 or NOAC) 3, 4
• 4 weeks of therapeutic anticoagulation after cardioversion 3, 4
• This applies regardless of CHA₂DS₂-VASc score or cardioversion method (electrical or pharmacological)

Alternative TEE-guided approach:

• Perform TEE to exclude left atrial thrombus
• If no thrombus: initiate therapeutic anticoagulation immediately before cardioversion
• Continue anticoagulation for at least 4 weeks post-cardioversion 3, 4

For AF/Flutter <48 Hours Duration

The evidence here is more nuanced, with recent data suggesting higher thromboembolic risk than previously recognized:

Canadian guidelines (2018) recommend immediate cardioversion without 3-week pre-treatment only for: 5

• Patients with clear AF onset within 12 hours AND no recent stroke/TIA (within 6 months)
• Patients with CHADS₂ score <2 presenting between 12-48 hours of onset

However, anticoagulation should still be initiated:

• Start IV heparin, LMWH, or NOAC at presentation 4, 6
• Continue therapeutic anticoagulation for at least 4 weeks post-cardioversion 4
• Recent evidence shows 0.7% thromboembolic risk even with acute AF <48 hours without anticoagulation 5

Hemodynamically Unstable Patients

Immediate cardioversion should not be delayed for anticoagulation 3, 7

However:

• Start IV heparin or LMWH as soon as possible, even if after cardioversion 4
• Continue therapeutic anticoagulation for at least 4 weeks post-cardioversion 4
• Long-term anticoagulation decisions based on CHA₂DS₂-VASc score, not cardioversion success

Pharmacological Cardioversion Options

Effective Agents (Class I Evidence)

For acute conversion: 3

• Flecainide: 50-200 mg every 12 hours (avoid in structural heart disease, CAD, heart failure)
• Dofetilide: Requires in-hospital initiation with continuous monitoring
• Propafenone: 150-300 mg every 8 hours (avoid in structural heart disease)
• IV Ibutilide: 1 mg over 10 minutes (3-4% risk of torsades de pointes; monitor QT interval)

Reasonable Alternatives (Class IIa)

• Amiodarone: 300 mg IV over 1 hour, then 10-50 mg/hour (slower conversion but safer in structural heart disease) 3, 8
• Vernakalant: 3 mg/kg IV over 10 minutes (avoid in SBP <100 mmHg, recent ACS, severe heart failure) 8

Critical Contraindications

Never use in pre-excited AF (Wolff-Parkinson-White): 3

• Digoxin
• Non-dihydropyridine calcium channel blockers (diltiazem, verapamil)
• IV amiodarone
• These agents can accelerate ventricular response and precipitate ventricular fibrillation

Post-Cardioversion Management

Duration of Anticoagulation

Minimum 4 weeks post-cardioversion for all patients 3, 4

Beyond 4 weeks:

• Base decision on stroke risk (CHA₂DS₂-VASc score), NOT on cardioversion success 5, 4
• Most thromboembolic events occur within 7-10 days post-cardioversion due to atrial stunning 7, 9
• Atrial mechanical function may take weeks to recover even after electrical restoration of sinus rhythm

NOAC vs. Warfarin

NOACs are reasonable alternatives to warfarin for peri-cardioversion anticoagulation 4

• Dabigatran, rivaroxaban, edoxaban, or apixaban acceptable
• Advantage: immediate therapeutic effect (no bridging needed)
• Disadvantage: requires strict adherence (no INR monitoring to verify compliance)
• For short-term use (<2 months), no proven efficacy or safety advantage over warfarin, but convenience favors NOACs 5

Common Pitfalls to Avoid

1. Don't withhold anticoagulation based on low CHA₂DS₂-VASc score: The cardioversion itself creates thromboembolic risk independent of baseline stroke risk 5, 9

2. Don't stop anticoagulation at 4 weeks if patient has stroke risk factors: The 4-week minimum is for cardioversion-related risk; long-term decisions require separate assessment 5, 4

3. Don't delay antiarrhythmic drugs for fear of spontaneous conversion: The ACUTE trial showed early AAD introduction is safe with appropriate anticoagulation 9

4. Don't use rate-control agents for rhythm control in pre-excitation: This can be fatal 3

5. Don't start dofetilide outpatient: Requires in-hospital monitoring due to QT prolongation risk 3

6. Don't use dronedarone for rate control in permanent AF: Increases risk of stroke, MI, and cardiovascular death 3